Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Immunother. 2012 Jun;35(5):385–389. doi: 10.1097/CJI.0b013e3182562d59

Figure 3.

Figure 3

C57/BL6 mice bearing established intracranial GL261 tumors had better long-term survival after treatment with sequential vaccination and CTLA-4 blockade (9H10 antibody given on days 12, 15, and 18) than did mice treated with either as monotherapy (figure is representative of 3 experiments, treating 8-10 mice per group).